Microbiome-Directed Therapies
Updates on Investigational Microbiome-Directed Therapies for Recurrent C Difficile Infection From IDWeek 2021
Teena Chopra
Teena Chopra, MD, MPH

Pretest

Progress
1 2
Course Completed
1.

Across studies of the microbiota-based live biotherapeutic RBX2660, what proportion of patients reached the primary endpoint of treatment success (absence of diarrhea due to recurrent Clostridioides difficile infection through 8 weeks post treatment)?